Last reviewed · How we verify
PF-04457845, FAAH inhibitor
At a glance
| Generic name | PF-04457845, FAAH inhibitor |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD) (PHASE2)
- Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal (PHASE2)
- FAAH Inhibitor Trial for Adults With Tourette Syndrome (PHASE1)
- A Study To Investigate Whether PF-04457845 Is Effective In Treating Pain, Is Safe And Tolerable In Patients With Osteoarthritis Of The Knee (PHASE2)
- A Multiple Dose Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04457845 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-04457845, FAAH inhibitor CI brief — competitive landscape report
- PF-04457845, FAAH inhibitor updates RSS · CI watch RSS
- Pfizer portfolio CI